Abstract
This paper provides a summary of recommendations from discussions held in Paris, France from April 26–29, 1992 on regulatory requirements for chiral drugs.
Get full access to this article
View all access options for this article.
Filter Results
Select search scope: search across all journals or within the current journal
Search this journal
Enter search terms…
/